Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation

Goichi Yoshimoto, Yasuo Mori, Koji Kato, Jun Odawara, Takuro Kuriyama, Toshiyuki Ueno, Teppei Obara, Ayano Yurino, Shuro Yoshida, Ryosuke Ogawa, Yuju Ohno, Hiromi Iwasaki, Tetsuya Eto, Koichi Akashi, Toshihiro Miyamoto

研究成果: Contribution to journalArticle査読

抄録

We retrospectively analyzed 38 patients with AML who received azacitidine (AZA) to treat disease relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with objective response (OR) (n = 20) after AZA had significantly higher 2-year overall survival (OS) (45.0% vs 5.6%; p = 0.004) than progressive disease. The 2-year OS was significantly higher in the retransplant group (n = 23) than in the nonretransplant group (n = 15) (34.8% vs 13.3%; p = 0.034). We analyzed 167 patients who underwent the second allo-HSCT to clarify the impact of pretransplant AZA after the second allo-HSCT. Patients in the AZA group (n = 21) had significantly higher 2-year disease-free survival (DFS) (32.7% vs 14.5%; p = 0.012) and OS (38.1% vs 17.5%; p = 0.044) than those in the SOC group (n = 146). Our data demonstrate that AZA is an effective and well-tolerated bridging therapy to the second allo-HSCT.

本文言語英語
ジャーナルLeukemia and Lymphoma
DOI
出版ステータス受理済み/印刷中 - 2021

All Science Journal Classification (ASJC) codes

  • 血液学
  • 腫瘍学
  • 癌研究

フィンガープリント

「Azacitidine for the treatment of patients with relapsed acute myeloid leukemia after allogeneic stem cell transplantation」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル